Feeder cell lines, like the modified K562 leukemia cells expressing IL-15 or the recent version expressing IL-21 and 4-1BBL, offer an alternative strategy for ex vivo expansion and are considered safer for clinical application [21,27]. This evidence concerns the gene IL15 and leukemia.